Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine condition that affects fertility through oligo-ovulation, hyperandrogenism and polycystic morphology of the ovaries. Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26). After the treatment, interval several endocrine parameters improved (luteinizing hormone [LH], LH/follicle stimulating hormone [FSH], androstenedione and insulin), insulin response to oral glucose tolerance test reported the significant improvement of insulin sensitivity as well as the gonadotropin-releasing hormone (GnRH)-induced (10 µg, in bolus) LH response. BMI decreased, though no lifestyle modification was requested. When data were analyzed according to the presence or absence of first-grade diabetic relatives, PCOS patients with diabetic relatives showed greater improvement after DCI administration. In conclusion DCI administration is effective in restoring better insulin sensitivity and an improved hormonal pattern in obese hyperinsulinemic PCOS patients, in particular, in hyperinsulinemic PCOS patients who have diabetic relatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“Hence the use of insulin sensitizers agents like metformin, rosiglitazone, pioglitazone and inositol [both MYO-inositol (MYO) and DCI] have been proposed [10,13,15,19,23,27,28].”
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · cited 1×
“determination of the best and most appropriate treatment to administer to PCOS patients [5,6], and some International Societies have clearly indicated the importance of evaluating the”
BackgroundGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 4×
“improved the average insulin sensitivity of the whole group of PCOS, together with LH and androgen plasma levels, similar to what was observed when administering MYO [14,23,29,30].”
BackgroundResultInfluentialSelf-citationEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Sun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144
Patel, K., Coffler, M. S., Dahan, M. H., Yoo, R. Y., Lawson, M. A., Malcom, P. J., & Chang, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030816 · Cited by 60 · cited 1×
“In fact, before treatment, LH response was greater than normal, similar to previous report [33], but under DCI administration, LH response to GnRH decreased thus suggesting a primary role of insulin-dependent metabolic pathway(s) on pituitary functions and/or gonadotropes sensitivity to GnRH, as it has been demonstrat…”
ResultUse of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Self-citationd-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
Galazis, N., Galazi, M., & Atiomo, W. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.538099 · Cited by 46 · cited 3×
“The most used insulin sensitizer is metformin but being able to induce relatively serious side effects such as abdominal discomfort, constipation, diarrhea, flatulence, heartburn, indigestion, nausea and vomiting [10], a greater interest has been given to more integrative interventions such as inositol [14,27].”
Background
Cited by
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
Inositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69
“According to available data, inositol treatment is especially highly effective among obese, hyperinsulinemic patients or patients with a positive family history of diabetes type two [38].”
BackgroundSelf-citationNutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome
Mansour, A., Hosseini, S., Larijani, B., & Mohajeri-Tehrani, M. R. (2016) · IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund · doi:10.17179/excli2016-422 · Cited by 15
“Similar effects were observed with the consumption of small amounts of D-chiro-inositol (500 mg/d) for 12 weeks in obese hyperinsulinemia PCOS women (Genazzani et al., 2014b).”
Result
Metadata
- Authors
- Genazzani, A. D., Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Marini, G., Prati, A., & Simoncini, T.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2014-03-07
- Volume
- 30
- Issue
- 6
- Pages
- 438-443
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2061584346
- Cited by
- 73
- References
- 10
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. https://app.cochat.ai/papers/10.3109/09513590.2014.897321
- The paper
- Genazzani, A. D., Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Marini, G., Prati, A., & Simoncini, T. (2014). Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2014.897321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.